Nanoparticle Formulations in the Diagnosis and Therapy of Alzheimer's Disease

Document Type

Article

Publication Date

2019

Keywords

Amyloid β peptide, Amyloid β aggregation, Alzheimer's disease, Nanoparticles formulations, Gold (Au) NPs, Adolinium NPs

Digital Object Identifier (DOI)

https://doi.org/10.1016/j.ijbiomac.2019.02.156

Abstract

Alzheimer's disease (AD) is one of the most common age-related diseases that occurs because of the deposition of amyloid fibrils in a form of extracellular plaques containing β-amyloid peptide (Aβ) and tangles are found as intracellular deposit in the brain made up of twisted strands of aggregated microtubule binding protein. Scores of small molecule inhibitors have been designed for the treatment of AD. However some of these drugs cannot pass through the brain-blood-barrier (BBB). To overcome this problem, various nanoparticles (NPs) or nanomedicines (NMs) have been synthesized. These nanoparticles exploit the existing physiological mechanisms of passing through the BBB, including receptor- and adsorptive-mediated transcytosis that facilitate the transcellular transport of nanoparticle from the blood to the brain. During the last decades, varieties of nanoparticles that differ in the composition have been developed, and they have the potential application in the diagnostics and therapy of AD. The most common NP formulations that have major impact in the diagnosis and therapy of AD include polymeric NPs (PPs), gold NPs, gadolinium NPs, selenium NPs, protein-based NPs, polysaccharide-based NPs, etc. The goal of this review is to provide discussion of the application of different types of NP formulations in the diagnosis and therapy of AD.

Was this content written or created while at USF?

Yes

Citation / Publisher Attribution

International Journal of Biological Macromolecules, v. 130, p. 515-526

Link to Full Text

Share

COinS